NASDAQ:TRVI

Trevi Therapeutics Stock Predictions

etoro logo Buy TRVI
*Your capital is at risk
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

TRVI Prediction Chart

TRVI Predictions History

Latest community submissions for TRVI.
Predictor Target Session Target Price Result Direction Accuracy Score
Sep 15, 2025 Bullish $8.07 X 0
Apr 28, 2025 $6.31 -2.51% $6.59 X 95.72% 0
Apr 28, 2025 $6.37 -1.57% $6.59 X 96.64% 0
Apr 28, 2025 Bullish $6.59 V 1
Apr 28, 2025 Bullish $6.59 V 1
Apr 28, 2025 $7.16 +10.66% $6.59 V 91.35% 1
Apr 28, 2025 $6.47 +0.00% $6.59 X 98.18% 0
Dec 13, 2024 $3.52 -2.36% $4.17 X 84.30% 0
Dec 13, 2024 $3.46 -3.77% $4.17 X 83.08% 0
thedean2010 thedean2010 Merchant
Dec 13, 2024 Bullish $4.17 V 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for TRVI with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT TREVI THERAPEUTICS INC.
Trevi Therapeutics
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE